Cancer Care Ontario | Action Cancer Ontario

Guideline Development Groups (GDGs) are brought together to work on a guideline for a specific topic. Cancer Care Ontario’s Program in Evidence-Based...

Drug Funding Frequently Asked Questions

We’ve compiled the answers to many commonly asked questions about cancer drug costs and funding in Ontario.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Hepatic, Pancreatic and Biliary Tract Surgical Oncology Standards

Dasatinib for the Treatment of Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia

Docetaxel plus Cyclophosphamide as Adjuvant Therapy for Early, Operable Breast Cancer

High-Intensity Focused Ultrasound for Prostate Cancer

Hyperbaric Oxygen Therapy for the Treatment and Prevention of Radionecrosis and Other Radiation-Induced Injuries in Cancer Patients

Hyperfractionated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in Advanced or Metastatic Adult Soft Tissue Sarcoma

Doxorubicin-Based Chemotherapy for the Palliative Treatment of Adult Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma

Healthy Eating, Physical Activity, and Healthy Weights Guideline for Public Health in Ontario

Diagnostic Imaging in Breast Cancer

How Guidelines Are Created

Drug Funding Frequently Asked Questions

Pages